

# National Institute for Health and Care Excellence

Final

## Intrapartum care

### Methods

*NICE guideline NG235*

*Supplement 1*

*September 2023*

*Final*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2023. All rights reserved. Subject to [Notice of Rights](#).

ISBN: 978-1-4731-5405-6.

# Contents

<b>Development of the guideline</b> .....	<b>5</b>
Remit .....	5
What this guideline update covers .....	5
What this guideline update does not cover .....	6
<b>Methods</b> .....	<b>7</b>
Developing the review questions and outcomes .....	7
Searching for evidence .....	9
Scoping search .....	9
Systematic literature search .....	9
Economic systematic literature search .....	9
Reviewing research evidence .....	10
Systematic review process .....	10
Type of studies and inclusion/exclusion criteria .....	11
Methods of combining evidence .....	11
Data synthesis for intervention studies .....	11
Appraising the quality of evidence .....	13
Intervention studies .....	13
Reviewing economic evidence .....	19
Appraising the quality of economic evidence .....	20
Economic modelling .....	20
Cost effectiveness criteria .....	21
Developing recommendations .....	21
Guideline recommendations .....	21
Research recommendations .....	21
Validation process .....	21
Updating the guideline .....	22
Funding .....	22
<b>References</b> .....	<b>23</b>

# Development of the guideline

## Remit

The National Institute for Health and Care Excellence (NICE) commissioned the National Guideline Alliance (NGA) to update the existing NICE clinical guideline on Intrapartum care for healthy women and babies (CG190, December 2014).

## What this guideline update covers

The 2023 update to this guideline includes evidence reviews in the following clinical areas:

- Place of birth – impact of body mass index (BMI) on place of birth
- Initial assessment of women – timeframe for review after reporting pre-labour rupture of membranes (PRoM)
- Care in established labour – fetal blood sampling
- Pain relief in labour: non-regional analgesia – water papules and intravenous patient-controlled analgesia (PCA)
- Pain relief in labour: regional analgesia – programmed intermittent epidural bolus
- First stage of labour – altering the dose and restarting oxytocin
- Second stage of labour – birth position with and without an epidural, pushing techniques, perineal care, prophylactic antibiotics in assisted birth
- Third stage of labour – active and physiological management, prevention and management of postpartum haemorrhage, position for cord clamping

In addition a number of editorial updates without evidence reviews are planned in the following areas:

- Place of birth – editorial changes to ensure consistency with current practice and about the information women are given about pain relief options at different places of birth
- Care throughout labour – language updates to the sections on communications and women's experience; removal of terminology 'supervisor of midwives'
- Latent first stage of labour – editorial changes to the current definitions for the latent and active first stages of labour, and the risk assessment that should be undertaken to determine the best place of care (including the incremental effect of several minor risk factors)
- Initial assessment - cross-referral to existing guidance for women who are group B streptococcus positive
- General principles for transfer of care – clarification of wording on what necessitates an urgent transfer and monitoring that should occur during transfer
- Care in established labour – changes to recommendations on controlling gastric acidity and fluid balance
- Pain relief in labour: non-regional analgesia – changes to include the environmental impact of entonox and the availability of TENS machines

- Pain relief in labour: regional analgesia – changes to recommendations on monitoring women with regional analgesia
- Monitoring during labour – simplification and clarification of CTG recommendations; clarification of the difference between antenatal and intrapartum CTG interpretation
- Second stage of labour – definitions for duration of second stage and definition of delay; clarification of analgesia/anaesthesia for assisted birth; dose of oxytocin if started in second stage
- Third stage of labour – risk factors for postpartum haemorrhage and ongoing nature of risk assessment; dose of oxygen and medications
- Care of the newborn baby – use of APGAR score in non-white babies; positioning during skin-to-skin contact

## **What this guideline update does not cover**

The following sections of the guideline will not be updated with an evidence review:

- Place of birth (except impact of BMI on place of birth)
- Care throughout labour
- Latent first stage of labour
- Initial assessment (except timeframe for review after reporting PROM)
- Ongoing assessment
- General principles for transfer of care
- Care in established labour (except fetal blood sampling)
- Pain relief in labour: non-regional analgesia (except water papules and intravenous PCA)
- Pain relief in labour: regional analgesia (except programmed intermittent epidural bolus)
- Monitoring during labour
- Prelabour rupture of membranes at term
- First stage of labour (except reducing the dose and restarting warfarin)
- Second stage of labour (except birth position with and without an epidural, pushing techniques, perineal care, prophylactic antibiotics in assisted birth)
- Third stage of labour (except active and physiological management, prevention and management of postpartum haemorrhage, position for cord clamping)
- Care of the newborn baby
- Care of the woman after birth

## Methods

This guideline was developed using the methods described in the 2018 NICE guidelines manual.

Declarations of interest were recorded according to the NICE conflicts of interest policy.

### Developing the review questions and outcomes

The review questions developed for this guideline were based on the key areas identified in the guideline [scope](#). They were drafted by the technical team and refined and validated by the guideline committee.

The review questions were based on the following frameworks:

- population, intervention, comparator and outcome (PICO) for reviews of interventions

Full literature searches, critical appraisals and evidence reviews were completed for all review questions.

The review questions and evidence reviews corresponding to each question (or group of questions) are summarised below.

**Table 1: Summary of review questions and index to evidence reviews**

Evidence review	Review question	Type of review
A	1.1 What are the benefits and risks of different places of birth for women at different BMI thresholds?	Intervention
B	2.1 What is the optimum timeframe between a mother reporting possible P <sub>RoM</sub> and face-to-face clinical review?	Intervention
C	3.1 What is the effectiveness of injected water papules for pain relief during labour?	Intervention
D	3.2 What is the effectiveness of remifentanil administered by intravenous patient-controlled analgesia (PCA) compared to other intramuscular opioids?	Intervention <sup>1</sup>
E	4.1 What is the effectiveness of Programmed Intermittent Epidural Bolus compared to other methods of maintaining epidural analgesia?	Intervention
F	6.1 What is the effectiveness of altering the dose of intravenous oxytocin to reduce excessive frequency of uterine contractions?	Intervention (both)

Evidence review	Review question	Type of review
	6.2 What is the optimum dose at which oxytocin should be restarted if stopped due to an abnormality in the CTG?	
G	7.1 What is the most effective position for birth in women with an epidural in situ? 7.2 What is the most effective position for birth in women without an epidural in situ?	Intervention
H	7.3 What are the benefits and risks of the different pushing techniques (immediate, spontaneous, delayed, directed) in the second stage of labour in women with and without regional analgesia?	Intervention
I	7.4 What is the effectiveness of perineal care in the second stage of labour (for example, massage, hands-on support and warm compresses) for reducing perineal trauma and tears?	Intervention
J	7.5 What is the effectiveness of prophylactic antibiotics for preventing postnatal infections in assisted vaginal birth?	Intervention
K	8.1 What are the benefits and risks associated with active management compared to physiological management in the third stage of labour?	Intervention
L	8.2 Is intravenous administration of oxytocin more effective than intramuscular administration in the active management of the third stage of labour?	Intervention
M	8.3 What is the effectiveness of uterotonics for the prevention of postpartum haemorrhage?	Intervention <sup>1</sup>
N	8.4 What is the optimum position for the baby during delayed cord clamping (including after instrumental and caesarean birth)?	Intervention
O	8.5 What is the effectiveness of pharmacological treatments for the management of postpartum haemorrhage?	Intervention

*BMI: body mass index; CTG: cardiotocography; PCA: patient-controlled analgesia; PRoM: pre-labour rupture of membranes*

*<sup>1</sup>Original health economic analysis conducted*

The COMET database was searched for core outcome sets relevant to this guideline. No core outcome sets were identified and therefore the outcomes were chosen based on committee discussions.

Additional information related to development of the guideline is contained in:

- Supplement 2 (Glossary and abbreviations)
- Supplement 3 (NGA developer staff list).

## Searching for evidence

### Scoping search

During the scoping phase, searches were conducted for previous guidelines, economic evaluations, health technology assessments, systematic reviews, randomised controlled trials, observational studies and qualitative research.

### Systematic literature search

Systematic literature searches were undertaken to identify published evidence relevant to each review question.

Databases were searched using subject headings, free-text terms and, where appropriate, study type filters. Where possible, searches were limited to retrieve studies published in English. Limits to exclude animal studies, letters, editorials, news and conferences were applied where possible. All the searches were conducted in the following databases: Medline, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Embase and International Network of Agencies for Health Technology Assessment (INAHTA).

Searches were run for all reviews during development. Searches for all questions were updated in August 2022, and then again for all questions except 1 in December 2022, 6 weeks in advance of the final committee meeting. The search for question 8.3 was not updated in December 2022 as the network meta-analysis based on the results of this search was underway and it was not possible to add additional data.

Details of the search strategies, including the study-design filters used and databases searched, are provided in Appendix B of each evidence review.

### Economic systematic literature search

Systematic literature searches were also undertaken to identify published economic evidence. Databases were searched using subject headings, free-text terms and, where appropriate, an economic evaluations search filter.

Searches using the search strategies derived from the review questions, combined with a search filter for economic evaluations, were conducted in Medline, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase. A single search, using the population search terms used in the evidence reviews, was also conducted in the International Network of Agencies for Health Technology Assessments (INAHTA) database. Where possible, searches were limited to studies published in

English. Limits to exclude animal studies, letters, editorials, news were applied where possible.

As with the general literature searches, the economic literature searches were run for all reviews during development. Searches for all questions were updated in August 2022, and then again for all questions except 1 in December 2022, 6 weeks in advance of the final committee meeting. The economic search for question 8.3 was not updated in December 2022 as the network meta-analysis and health economic modelling was underway and so additional health economic evidence was not prioritised.

Details of the search strategies, including the study-design filters used and databases searched, are provided in Appendix B of each evidence review.

## Quality assurance

Search strategies were quality assured by cross-checking reference lists of relevant studies, analysing search strategies from published systematic reviews and asking members of the committee to highlight key studies. The principal search strategies for each search were also quality assured by a second information scientist using an adaptation of the PRESS 2015 Guideline Evidence-Based Checklist (McGowan 2016). In addition, all publications highlighted by stakeholders at the time of the consultation on the draft scope were considered for inclusion.

## Reviewing research evidence

### Systematic review process

The evidence was reviewed in accordance with the following approach.

- Potentially relevant articles were identified from the search results for each review question by screening titles and abstracts. Full-text copies of the articles were then obtained.
- Full-text articles were reviewed against pre-specified inclusion and exclusion criteria in the review protocol (see Appendix A of each evidence review).
- Key information was extracted from each article on study methods and results, in accordance with factors specified in the review protocol. The information was presented in a summary table in the corresponding evidence review and in a more detailed evidence table (see Appendix D of each evidence review).
- Included studies were critically appraised using an appropriate checklist as specified in [Developing NICE guidelines: the manual](#). Further detail on appraisal of the evidence is provided below.
- Summaries of effectiveness evidence by outcome were presented in the corresponding evidence review and discussed by the committee.

Review questions informing network meta-analyses (NMA), selected as high priorities for economic analysis (and those selected as medium priorities and where economic analysis could influence recommendations) and complex review questions were subject to dual screening and study selection through a 10% random sample of articles. Any discrepancies were resolved by discussion between the first and second reviewers or by reference to a third (senior) reviewer. For the remaining review questions, internal (NGA) quality assurance processes included consideration of the

outcomes of screening, study selection and data extraction and the committee reviewed the results of study selection and data extraction. The review protocol for each question specifies whether dual screening and study selection was undertaken for that particular question. Drafts of all evidence reviews were quality assured by a senior reviewer.

## **Type of studies and inclusion/exclusion criteria**

Inclusion and exclusion of studies was based on criteria specified in the corresponding review protocol. A study was considered indirect if 1% to 33% of the population included had any of the characteristics included in the exclusion criteria of the review protocol.

Systematic reviews (SRs) with meta-analyses were considered to be the highest quality evidence that could be selected for inclusion.

For intervention reviews, randomised controlled trials (RCTs) were prioritised for inclusion because they are considered to be the most robust type of study design that could produce an unbiased estimate of intervention effects. Where there was limited evidence from RCTs, non-randomised studies (NRS) were considered for inclusion.

The committee was consulted about any uncertainty regarding inclusion or exclusion of studies. A list of excluded studies for each review question, including reasons for exclusion is presented in Appendix J of the corresponding evidence review.

Narrative reviews, posters, letters, editorials, comment articles, unpublished studies and studies published in languages other than English were excluded. Conference abstracts were not considered for inclusion because conference abstracts typically do not have sufficient information to allow for full critical appraisal.

## **Methods of combining evidence**

When planning reviews (through preparation of protocols), the following approaches for data synthesis were discussed and agreed with the committee.

### **Data synthesis for intervention studies**

#### ***Pairwise meta-analysis***

Meta-analysis to pool results from comparative intervention studies was conducted where possible using Cochrane Review Manager (RevMan5) software.

For dichotomous outcomes, such as mortality, the Mantel–Haenszel method with a fixed effect model was used to calculate risk ratios (RRs). For all outcomes with zero events in both arms or in meta-analysis where some studies reported 0 events in both arms, the risk difference was presented. For outcomes in which the majority of studies had low event rates (<1%) or 0 events in 1 arm but not in the other, Peto odds ratios (PORs) were calculated as this method performs well when events are rare (Bradburn 2007).

For continuous outcomes, measures of central tendency (mean) and variation (standard deviation; SD) are required for meta-analysis. Data for continuous outcomes, such as quality of life, were meta-analysed using an inverse-variance

method for pooling weighted mean differences (WMDs). Where SDs were not reported for each intervention group, the standard error (SE) of the mean difference was calculated from other reported statistics (p-values or 95% confidence intervals [CIs]) and then meta-analysis was conducted as described above.

If a study reported only the summary statistic and 95% CI, the generic-inverse variance method was used to enter data into RevMan5. If the control event rate was reported this was used to generate the absolute risk difference in GRADEpro. If multivariable analysis was used to derive the summary statistic but no adjusted control event rate was reported, no absolute risk difference was calculated.

When evidence was based on studies that reported descriptive data or medians with interquartile ranges or p values, this information was included in the corresponding GRADE tables (see below) without calculating relative or absolute effects. Consequently, certain aspects of quality assessment such as imprecision of the effect estimate could not be assessed as per standard methods for this type of evidence and subjective ratings or ratings based on sample size cut-offs were considered instead.

For some reviews, evidence was either stratified from the outset or separated into subgroups when heterogeneity was encountered. The stratifications and potential subgroups were pre-defined at the protocol stage (see the protocols for each review for further detail). Where evidence was stratified or subgrouped the committee considered on a case by case basis if separate recommendations should be made for distinct groups. Separate recommendations may be made where there is evidence of a differential effect of interventions in distinct groups. If there is a lack of evidence in one group, the committee considered, based on their experience, whether it was reasonable to extrapolate and assume the interventions will have similar effects in that group compared with others.

When meta-analysis was undertaken, the results were presented visually using forest plots generated using RevMan5 (see Appendix E of relevant evidence reviews).

### **Network meta-analysis**

As is the case for ordinary pairwise meta-analysis, network meta-analysis (NMA) may be conducted using either fixed or random effect models. A fixed effect model typically assumes that there is no variation in relative effects across trials for a particular pairwise comparison and any observed differences are solely due to chance. For a random effects model, it is assumed that the relative effects are different in each trial but that they are from a single common distribution. The variance reflecting heterogeneity is often assumed to be constant across trials.

In a Bayesian analysis, for each parameter the evidence distribution is weighted by a distribution of prior beliefs. The Markov chain Monte Carlo (MCMC) algorithm was used to generate a sequence of samples from a joint posterior distribution of 2 or more random variables and is particularly well adapted to sampling the treatment effects (known as a posterior distribution) of a Bayesian network. A prior distribution was used to maximise the weighting given to the data and to generate the posterior distribution of the results.

For the analyses, a series of burn-in simulations were run to allow the posterior distributions to converge and then further simulations were run to produce the posterior outputs. Convergence was assessed by examining the history, autocorrelation and Brooks-Gelman-Rubin plots.

Goodness-of-fit of the model was also estimated by using the posterior mean of the sum of the deviance contributions for each item by calculating the residual deviance and deviance information criteria (DIC). If the residual deviance was close to the number of unconstrained data points (the number of trial arms in the analysis) then the model was explaining the data at a satisfactory level. The choice of a fixed effect or random effects model can be made by comparing their goodness-of-fit to the data. Treatment specific posterior effects were generated for every possible pair of comparisons by combining direct and indirect evidence in each network. The probability that each treatment is best, based on the proportion of Markov chain iterations in which the treatment effect for an intervention is ranked best, second best and so forth. This was calculated by taking the treatment effect of each intervention compared to the reference treatment and counting the proportion of simulations of the Markov chain in which each intervention had the highest treatment effect.

We adapted standard fixed and random effects models available from NICE Decision Support Unit (DSU) technical support document number 2:

<http://nicedsu.org.uk/wpcontent/uploads/2017/05/TSD2-General-meta-analysis-corrected-2Sep2016v2.pdf>

To determine if there is evidence of inconsistency, the selected consistency model (fixed or random effects) was compared to an “inconsistency”, or unrelated mean effects, model. We performed further checks for evidence of inconsistency through node-splitting.

For further description of the NMA and health economic model used for review question 8.3 What is the effectiveness of uterotonics for the prevention of postpartum haemorrhage? including specific methods, outcomes and the results of the NMA please see evidence report M Uterotonics for the prevention of postpartum haemorrhage.

The quality assurance of all the NMA work was undertaken by the NICE Guidelines Technical Support Unit, University of Bristol (TSU).

## Appraising the quality of evidence

### Intervention studies

#### *Pairwise meta-analysis*

##### **GRADE methodology for intervention reviews**

For intervention reviews, the evidence for outcomes from included RCTs and comparative non-randomised studies was evaluated and presented using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology developed by the international GRADE working group.

When GRADE was applied, software developed by the GRADE working group (GRADEpro) was used to assess the quality of each outcome, taking account of individual study quality factors and any meta-analysis results. Results were presented in GRADE profiles (GRADE tables).

The selection of outcomes for each review question was agreed during development of the associated review protocol in discussion with the committee. The evidence for each outcome was examined separately for the quality elements summarised in

Table 2. Criteria considered in the rating of these elements are discussed below. Each element was graded using the quality ratings summarised in Table 3. Footnotes to GRADE tables were used to record reasons for grading a particular quality element as having a 'serious' or 'very serious' quality issue. The ratings for each component were combined to obtain an overall assessment of quality for each outcome as described in Table 4.

The initial quality rating was based on the study design: RCTs and NRS assessed by ROBINS-I start as 'high' quality evidence, other non-randomised studies start as 'low' quality evidence. The rating was then modified according to the assessment of each quality element (Table 2). Each quality element considered to have a 'serious' or 'very serious' quality issue was downgraded by 1 or 2 levels respectively (for example, evidence starting as 'high' quality was downgraded to 'moderate' or 'low' quality). In addition, there was a possibility to upgrade evidence from non-randomised studies (provided the evidence for that outcome had not previously been downgraded) if there was a large magnitude of effect, a dose–response gradient, or if all plausible confounding would reduce a demonstrated effect or suggest a spurious effect when results showed no effect.

**Table 2: Summary of quality elements in GRADE for intervention reviews**

Quality element	Description
Risk of bias ('Study limitations')	This refers to limitations in study design or implementation that reduce the internal validity of the evidence
Inconsistency	This refers to unexplained heterogeneity in the results
Indirectness	This refers to differences in study populations, interventions, comparators or outcomes between the available evidence and inclusion criteria specified in the review protocol. An outcome was downgraded for indirectness if there was a significant difference ( $p < 0.5$ ) between the treatment arms for any of the items in the exclusion criteria of the review protocol or if a study did not report on items in the exclusion criteria of the review protocol
Imprecision	This occurs when a study has few participants or few events of interest, resulting in wide confidence intervals that cross minimally important differences
Publication bias	This refers to systematic under- or over-estimation of the underlying benefit or harm resulting from selective publication of study results

**Table 3: GRADE quality ratings (by quality element)**

Quality issues	Description
None or not serious	No serious issues with the evidence for the quality element under consideration
Serious	Issues with the evidence sufficient to downgrade by 1 level for the quality element under consideration
Very serious	Issues with the evidence sufficient to downgrade by 2 levels for the quality element under consideration

**Table 4: Overall quality of the evidence in GRADE (by outcome)**

Overall quality grading	Description
High	Further research is very unlikely to change the level of confidence in the estimate of effect
Moderate	Further research is likely to have an important impact on the level of confidence in the estimate of effect and may change the estimate
Low	Further research is very likely to have an important impact on the level of confidence in the estimate of effect and is likely to change the estimate
Very low	The estimate of effect is very uncertain

### *Assessing risk of bias in intervention reviews*

Bias is a systematic error, or consistent deviation from the truth in results obtained. When a risk of bias is present the true effect can be either under- or over-estimated.

Risk of bias in RCTs was assessed using the Cochrane risk of bias v2 tool (see Appendix H in Developing NICE guidelines: the manual).

The Cochrane risk of bias tool assesses the following possible sources of bias:

- Bias arising from the randomisation process
- Bias due to deviations from the intended interventions
- Bias due to missing outcome data
- Bias in measurement of the outcome
- Bias in selection of the reported results

A study with a poor methodological design does not automatically imply high risk of bias; the bias is considered individually for each outcome and it is assessed whether the chosen design and methodology will impact on the estimation of the intervention effect.

More details about the Cochrane risk of bias tool can be found in Section 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011, updated 2019).

For systematic reviews of RCTs the AMSTAR checklist was used and for systematic reviews of other study types the ROBIS checklist was used (see Appendix H in Developing NICE guidelines: the manual).

For non-randomised studies the ROBINS-I checklist was used (see Appendix H in Developing NICE guidelines: the manual).

### *Assessing inconsistency in intervention reviews*

Inconsistency refers to unexplained heterogeneity in results of meta-analysis. When estimates of treatment effect vary widely across studies (that is, there is heterogeneity or variability in results), this suggests true differences in underlying effects. Inconsistency is, thus, only truly applicable when statistical meta-analysis is conducted (that is, results from different studies are pooled). When outcomes were derived from a single study the rating 'no serious inconsistency' was used when assessing this domain, as per GRADE methodology (Santesso 2016).

Inconsistency was assessed visually by inspecting forest plots and observing whether there was considerable heterogeneity in the results of the meta-analysis (for example if the point estimates of the individual studies consistently showed benefits or harms). This was supported by calculating the I-squared statistic for the meta-analysis with an I-squared value of more than 50% indicating serious heterogeneity, and more than 80% indicating very serious heterogeneity. When serious or very serious heterogeneity was observed, possible reasons were explored and subgroup analyses were performed as pre-specified in the review protocol where possible.

When no plausible explanation for the serious or very serious heterogeneity could be found, the quality of the evidence was downgraded in GRADE for inconsistency and the meta-analysis was re-run using the Der-Simonian and Laird method with a random effects model and this was used for the final analysis.

#### *Assessing indirectness in intervention reviews*

Directness refers to the extent to which populations, interventions, comparisons and outcomes reported in the evidence are similar to those defined in the inclusion criteria for the review and was assessed by comparing the PICO elements in the studies to the PICO defined in the review protocol. Indirectness is important when such differences are expected to contribute to a difference in effect size, or may affect the balance of benefits and harms considered for an intervention.

#### *Assessing imprecision and importance in intervention reviews*

Imprecision in GRADE methodology refers to uncertainty around the effect estimate and whether or not there is an important difference between interventions (that is, whether the evidence clearly supports a particular recommendation or appears to be consistent with several candidate recommendations). Therefore, imprecision differs from other aspects of evidence quality because it is not concerned with whether the point estimate is accurate or correct (has internal or external validity). Instead, it is concerned with uncertainty about what the point estimate actually represents. This uncertainty is reflected in the width of the CI.

The 95% CI is defined as the range of values within which the population value will fall on 95% of repeated samples, were the procedure to be repeated. The larger the study, the smaller the 95% CI will be and the more certain the effect estimate.

Imprecision was assessed in the guideline evidence reviews by considering whether the width of the 95% CI of the effect estimate was relevant to decision making, considering each outcome independently. This is illustrated in Figure 1, which considers a positive outcome for the comparison of two treatments. Three decision-making zones can be differentiated, bounded by the thresholds for minimal importance (minimally important differences [MIDs]) for benefit and harm.


When the 95% CI of the effect estimate is wholly contained in 1 of the 3 zones there is no uncertainty about the size and direction of effect, therefore, the effect estimate is considered precise; that is, there is no imprecision.

When the 95% CI crosses 2 zones, it is uncertain in which zone the true value of the effect estimate lies and therefore there is uncertainty over which decision to make. The CI is consistent with 2 possible decisions, therefore, the effect estimate is considered to be imprecise in the GRADE analysis and the evidence is downgraded by 1 level ('serious imprecision').

When the 95% CI crosses all 3 zones, the effect estimate is considered to be very imprecise because the CI is consistent with 3 possible decisions and there is therefore a considerable lack of confidence in the results. The evidence is therefore downgraded by 2 levels in the GRADE analysis ('very serious imprecision').

Implicitly, assessing whether a CI is in, or partially in, an important zone, requires the guideline committee to estimate an MID or to say whether they would make different decisions for the 2 confidence limits.

**Figure 1: Assessment of imprecision and importance in intervention reviews using GRADE**



*MID: minimally important difference*

#### *Defining minimally important differences for intervention reviews*

The committee was asked whether there were any recognised or acceptable MIDDs in the published literature and community relevant to the review questions under consideration. The committee was not aware of any MIDDs that could be used for the guideline.

In the absence of published or accepted MIDDs, the committee agreed to use the GRADE default MIDDs to assess imprecision. For dichotomous outcomes minimally important thresholds for a RR of 0.8 and 1.25 respectively were used as default MIDDs in the guideline. The committee also chose to use 0.8 and 1.25 as the MIDDs for ORs & HRs in the absence of published or accepted MIDDs. ORs were predominantly used in the guideline when Peto OR were indicated due to low event rates, at low event rates OR are mathematically similar to RR making the extrapolation appropriate. While no default MIDDs exist for HR, the committee agreed for consistency to continue to use 0.8 and 1.25 for these outcomes.

If risk difference was used for meta-analysis, for example if the majority of studies had zero events in either arm, imprecision was assessed based on sample size using 200 and 400 as cut-offs for very serious and serious imprecision respectively. The committee used these numbers based on commonly used optimal information size thresholds.

The same thresholds were used as default MIDDs in the guideline for all dichotomous outcomes considered in intervention evidence reviews. For continuous outcomes default MIDDs are equal to half the median SD of the control groups at baseline (or at follow-up if the SD is not available a baseline).

MIDs, the line of no effect, and both 95% and 90% confidence intervals (CIs) were used to assess whether there were important differences in outcomes between groups. Outcomes were considered to have an important benefit/harm, possible important benefit/harm, no evidence of an important difference, or no important difference using the following approach:

- Where the point estimate (PE) is greater than the upper MID and the 95% CI do not cross line of no effect, an intervention was described as having an important benefit
- Where the PE is greater than the upper MID and the 95% CI do cross the line of no effect, but the 90% CI do not, an intervention was described as having a possible important benefit
- Where the PE is greater than the upper MID **or** lower than the lower MID, and the 90% CI cross the line of no effect, the result was described as no evidence of an important difference
- Where the PE is between two MIDs, the result was described as no important difference
- Where the PE is lower than the lower MID and the 95% CI do cross the line of no effect, but the 90% CI do not, an intervention is described as having a possible important harm
- Where the PE is lower than the lower MID and the 95% CI do not cross line of no effect, an intervention was described as having an important harm.

This approach was used for all evidence reviews which informed decision making on the guideline, including when interpreting results from evidence reviews conducted by the Cochrane Collaboration. Please note that the above descriptions are based on positive outcomes (where high values indicate better outcomes or events are positive). If the outcomes were negative (where high values indicate worse outcomes or events are negative) then whether an intervention is considered to have an important benefit or important harm would be switched (for example, where the PE is greater than the upper MID and the 95% CI do not cross line of no effect, an intervention would be described as having an important harm; where the PE is lower than the lower MID and the 95% CI do not cross line of no effect, an intervention would be described as having an important benefit).

90% CI are reported in the summary of the evidence section of the evidence reviews only when they were used to determine a possible importance difference (that is, when interventions had a possible important benefit/ harm).

#### *Assessing publication bias in intervention reviews*

Where 10 or more studies were included as part of a single meta-analysis, a funnel plot was produced to graphically assess the potential for publication bias. However no enough studies were included in a single meta-analysis, therefore the committee subjectively assessed the likelihood of publication bias based on factors such as the proportion of trials funded by industry and the propensity for publication bias in the topic area.

### **Network meta-analysis**

For the NMA, quality was assessed by looking at risk of bias across the included evidence using the Cochrane Risk of Bias Tool for Randomized Controlled Trials, as well as heterogeneity and consistency (also called incoherence).

The following limits of the upper 95% credible interval (CrI) for between-study standard deviation were used to assess heterogeneity for NMAs in which a random effects model was used:

- less than 0.3 – low heterogeneity
- 0.3 to 0.6 – moderate heterogeneity
- more than 0.6 to 0.9 – high heterogeneity
- more than 0.9 to 1.2 – very high heterogeneity

The consistency between direct and indirect evidence can be assessed in closed treatment loops within the network. These closed treatment loops are regions within a network where direct evidence is available on at least 3 different treatments that form a closed ‘circuit’ of treatment comparisons (for example, A versus B, B versus C, C versus A). If closed treatment loops existed then discrepancies between direct and indirect evidence was assessed.

To determine if there is evidence of inconsistency, the selected consistency model (fixed or random effects) was compared to an “inconsistency”, or unrelated mean effects, model. The latter is equivalent to having separate, unrelated, meta-analyses for every pairwise contrast, with a common variance parameter assumed in the case of random effects models. Further checks for evidence of inconsistency either through Bucher’s method or node-splitting were undertaken. Bucher’s method compares the direct and indirect estimates for a contrast in a loop (e.g., A-B-C) where the direct estimate of contrast B vs. C is compared to its corresponding indirect estimate, which is informed from the direct estimates of the other contrasts in the loop (A vs. B and A vs. C). This method was used to assess consistency in networks, where there was a single loop and the network contained sparse evidence with zero events, limiting the stability of the results of more sophisticated methods such as the node-splitting method. The node-splitting method allowed the direct and indirect evidence contributing to an estimate of a relative effect to be split and compared. The consistency checks were undertaken by the TSU.

For fixed-effect NMAs that did not model heterogeneity, or for networks in which inconsistency could not be assessed as no closed treatment loops existed, these criteria were not considered to impact the quality of evidence.

## **Reviewing economic evidence**

Titles and abstracts of articles identified through the economic literature searches were independently assessed for inclusion using the predefined eligibility criteria listed in Table 5.

**Table 5: Inclusion and exclusion criteria for systematic reviews of economic evaluations**

Inclusion criteria
Intervention or comparators in accordance with the guideline scope

Inclusion criteria
Study population in accordance with the guideline scope
Full economic evaluations (cost-utility, cost effectiveness, cost-benefit or cost-consequence analyses) assessing both costs and outcomes associated with interventions of interest
Exclusion criteria
Abstracts containing insufficient methodological details
Cost-of-illness type studies

Once the screening of titles and abstracts was completed, full-text copies of potentially relevant articles were requested for detailed assessment. Inclusion and exclusion criteria were applied to articles obtained as full-text copies.

Details of economic evidence study selection, lists of excluded studies and, economic evidence tables are presented in appendices G, H and J of the evidence report. The results of quality assessment of economic evidence (see below) and health economic profiles are provided in the main body of the evidence review.

## Appraising the quality of economic evidence

The quality of economic evidence was assessed using the economic evaluations checklist specified in [Developing NICE guidelines: the manual](#).

## Economic modelling

The aims of the economic input to the guideline were to inform the guideline committee of potential economic issues to ensure that recommendations represented a cost effective use of healthcare resources. Economic evaluations aim to integrate data on healthcare benefits (ideally in terms of quality-adjusted life-years; QALYs) with the costs of different options. In addition, the economic input aimed to identify areas of high resource impact; these are recommendations which (while cost effective) might have a large impact on Clinical Commissioning Group or Trust finances and so need special attention.

The guideline committee prioritised the following review questions for economic modelling where it was thought that economic considerations would be particularly important in formulating recommendations.

- Evidence review D: What is the effectiveness of remifentanyl administered by intravenous patient-controlled analgesia (PCA) compared to other opioid intramuscular administration?
- Evidence review M: What is the effectiveness of uterotonic (for example, oxytocin and carbetocin) for the prevention of postpartum haemorrhage?

The methods and results of the de novo economic analyses are reported in Appendix I of the relevant evidence reports. When new economic analysis was not prioritised, the committee made a qualitative judgement regarding cost effectiveness by considering expected differences in resource and cost use between options, alongside clinical effectiveness evidence identified from the clinical evidence review.

## Cost effectiveness criteria

NICE's sets out the [principles](#) that committees should consider when judging whether an intervention offers good value for money. In general, an intervention was considered to be cost effective if any of the following criteria applied (provided that the estimate was considered plausible):

- the intervention dominated other relevant strategies (that is, it was both less costly in terms of resource use and more effective compared with all the other relevant alternative strategies)
- the intervention cost less than £20,000 per QALY gained compared with the next best strategy
- the intervention provided important benefits at an acceptable additional cost when compared with the next best strategy.

The committee's considerations of cost effectiveness are discussed explicitly under the heading 'Consideration of economic benefits and harms' in the relevant evidence reviews.

## Developing recommendations

### Guideline recommendations

Recommendations were drafted on the basis of the committee's interpretation of the available evidence, taking account of the balance of benefits, harms and costs between different courses of action. When effectiveness, qualitative and economic evidence was of poor quality, conflicting or absent, the committee drafted recommendations based on their expert opinion. The considerations for making consensus-based recommendations include the balance between potential benefits and harms, the economic costs or implications compared with the economic benefits, current practices, recommendations made in other relevant guidelines, person's preferences and equality issues.

The main considerations specific to each recommendation are outlined under the heading 'The committee's discussion of the evidence' within each evidence review.

For further details refer to Developing NICE guidelines: the manual.

### Research recommendations

When areas were identified for which evidence was lacking, the committee considered making recommendations for future research. For further details refer to Developing NICE guidelines: the manual and NICE's Research recommendations process and methods guide.

## Validation process

This guideline was subject to a 6-week public consultation and feedback process. All comments received from registered stakeholders were responded to in writing and posted on the NICE website at publication. For further details refer to Developing NICE guidelines: the manual.

## **Updating the guideline**

Following publication, NICE will undertake a surveillance review to determine whether the evidence base has progressed sufficiently to consider altering the guideline recommendations and warrant an update. For further details refer to *Developing NICE guidelines: the manual*.

## **Funding**

The NGA was commissioned by NICE to develop this guideline. During development, in April 2022, the NGA transferred into NICE and thereafter the guideline development process was directly managed by NICE.

# References

## **Bradburn 2007**

Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Localio, A. R. Much ado about nothing: A comparison of the performance of meta-analytical methods with rare events. *Statistics in Medicine*, 26, 53–77, 2007.

## **Higgins 2011**

Higgins JPT, Green S (editors) (2011) *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated 2019]* The Cochrane Collaboration. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org) (accessed 21 April 2023)

## **McGowan 2016**

McGowan J, Sampson M, Salzwedel DM et al. (2016) [PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement](#). *Journal of Clinical Epidemiology* 75: 40–6

## **NICE 2014**

National Institute for Health and Care Excellence (NICE), *Developing NICE guidelines: the manual* (<https://www.nice.org.uk/process/pmg20/chapter/introduction>)

## **NICE 2018**

National Institute for Health and Care Excellence (NICE) (2014) *NICE Policy on conflicts of interest* (updated 2017). Available from <https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/declaration-of-interests-policy.pdf> (accessed 21 April 2023)

## **Santesso 2016**

Santesso N, Carrasco-Labra A, Langendam M et al. (2016) Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments. *Journal of clinical epidemiology* 74, 28-39